Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Reticulophagy-a new target for diseases prevention and treatment

Progress on the Autophagic Regulators and Receptors in Plants.

The Spatiotemporal Control of ER Membrane Fragmentation During Reticulophagy.

Enhancing neuronal reticulophagy: a strategy for combating aging and APP toxicity

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies

Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives

Reticulon Homology Domain-Containing Proteins and ER-Phagy

Glycophagy: An emerging target in pathology

Targeting Autophagy to Overcome Human Diseases

ER-Phagy: A New Regulator of ER Homeostasis

Visualization of Reticulophagy in Living Cells Using an Endoplasmic Reticulum-Targeted P62 Mutant

Selective autophagy of intracellular organelles: Recent research advances

Autophagy and new strategy for cancer prevention and treatment

Targeting autophagy in disease: established and new strategies

Reticulophagy mediated by the V-ATPase-ATG16L1-LC3C axis

ER-Phagy, ER Homeostasis, and ER Quality Control: Implications for Disease

Induction mechanisms of autophagy and endoplasmic reticulum stress in intestinal ischemia-reperfusion injury, inflammatory bowel disease, and colorectal cancer

ER‐phagy: shaping up and destressing the endoplasmic reticulum

Molecular Modulators and Receptors of Selective Autophagy: Disease Implication and Identification Strategies

Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches

Autophagy in Aging and Neurodegenerative Diseases: Implications for Pathogenesis and Therapy.